Soluble heparan sulfate fragments generated by heparanase trigger the release of pro-inflammatory cytokines through TLR-4

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Goodall, Katharine J ^a,b   Poon, Ivan K H ^a   Phipps, Simon ^c   Hulett, Mark D ^a  

^a LA TROBE UNIVERSITY   (Australia)

^b School of Earth and Environmental Sciences   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARAN SULFATE; HEPARANASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; BETA GLUCURONIDASE; CYTOKINE; TLR4 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE RESPONSE; ENZYME ACTIVITY; EX VIVO STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; ANIMAL; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; EXTRACELLULAR SPACE; GENE EXPRESSION REGULATION; METABOLISM; MONONUCLEAR CELL; SECRETION (PROCESS); SOLUBILITY;

ANIMALS; CYTOKINES; EXTRACELLULAR SPACE; GENE EXPRESSION REGULATION; GLUCURONIDASE; HEPARITIN SULFATE; HUMANS; LEUKOCYTES, MONONUCLEAR; MICE; MYELOID DIFFERENTIATION FACTOR 88; SIGNAL TRANSDUCTION; SOLUBILITY; TOLL-LIKE RECEPTOR 4;

EID: 84907829494     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109596     Document Type: Article

References (65)

1. Holmdahl R, Malmstrom V, Burkhardt H (2014) Autoimmune priming, tissue attack and chronic inflammation - The three stages of rheumatoid arthritis. Eur J Immunol 44: 1593-1599.
2. Golia E, Limongelli G, Natale F, Fimiani F, Maddaloni V, et al. (2014) Inflammation and cardiovascular disease: from pathogenesis to therapeutic target. Curr Atheroscler Rep 16: 435.
3. Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105: 1135-1143.
4. Mora C, Navarro JF (2006) Inflammation and diabetic nephropathy. Curr Diab Rep 6: 463-468.
5. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144: 646-674.
6. Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA (2014) Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014: 149185.
7. Korpos E, Wu C, Song J, Hallmann R, Sorokin L (2010) Role of the extracellular matrix in lymphocyte migration. Cell Tissue Res 339: 47-57.
8. Friedl P, Brocker EB (2000) The biology of cell locomotion within three dimensional extracellular matrix. Cell Mol Life Sci 57: 41-64.
9. Simon Davis DA, Parish CR (2013) Heparan sulfate: A ubiquitous glycosaminoglycan with multiple roles in immunity. Front Immunol 4: 470.
10. Parish CR (2006) The role of heparan sulphate in inflammation. Nat Rev Immunol 6: 633-643.
11. Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, et al. (1999) Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med 5: 803-809.
12. Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, et al. (1999) Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med 5: 793-802.
13. Arvatz G, Shafat I, Levy-Adam F, Ilan N, Vlodavsky I (2011) The heparanase system and tumor metastasis: is heparanase the seed and soil? Cancer Metastasis Rev 30: 253-268.
14. Nasser NJ (2008) Heparanase involvement in physiology and disease. Cell Mol Life Sci 65: 1706-1715.
15. Goldberg R, Meirovitz A, Hirshoren N, Bulvik R, Binder A, et al. (2013) Versatile role of heparanase in inflammation. Matrix Biol 32: 234-240.
16. Parish CR, Freeman C, Hulett MD (2001) Heparanase: A key enzyme involved in cell invasion. Biochim Biophys Acta 1471: M99-M108.
17. Goldshmidt O, Zcharia E, Cohen M, Aingorn H, Cohen I, et al. (2003) Heparanase mediates cell adhesion independent of its enzymatic activity. FASEB J 17: 1015-1025.
18. Gilat D, Hershkoviz R, Goldkorn I, Cahalon L, Korner G, et al. (1995) Molecular behavior adapts to context: heparanase functions as an extracellular matrix-degrading enzyme or as a T cell adhesion molecule, depending on the local pH. J Exp Med 181: 1929-1934.
19. Gingis-Velitski S, Zetser A, Flugelman MY, Vlodavsky I, Ilan N (2004) Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J Biol Chem 279: 23536-23541.
20. Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296: 1655- 1657.
21. Schmidt EP, Yang Y, Janssen WJ, Gandjeva A, Perez MJ, et al. (2012) The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. Nat Med 18: 1217-1223.
22. Vlodavsky I, Blich M, Li JP, Sanderson RD, Ilan N (2013) Involvement of heparanase in atherosclerosis and other vessel wall pathologies. Matrix Biol 32: 241-251.
23. Zcharia E, Metzger S, Chajek-Shaul T, Aingorn H, Elkin M, et al. (2004) Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior. FASEB J 18: 252-263.
24. Zcharia E, Zilka R, Yaar A, Yacoby-Zeevi O, Zetser A, et al. (2005) Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models. FASEB J 19: 211-221.
25. Parish CR, Freeman C, Ziolkowski AF, He YQ, Sutcliffe EL, et al. (2013) Unexpected new roles for heparanase in Type 1 diabetes and immune gene regulation. Matrix Biol 32: 228-233.
26. Simeonovic CJ, Ziolkowski AF, Wu Z, Choong FJ, Freeman C, et al. (2013) Heparanase and Autoimmune Diabetes. Front Immunol 4: 471.
27. Lygizos MI, Yang Y, Altmann CJ, Okamura K, Hernando AA, et al. (2013) Heparanase mediates renal dysfunction during early sepsis in mice. Physiol Rep 1: e00153.
28. Blich M, Golan A, Arvatz G, Sebbag A, Shafat I, et al. (2013) Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression. Arterioscler Thromb Vasc Biol 33: e56-e65.
29. Lerner A (2011) Balanced polymorphism: A survival advantage in celiac disease. Med Hypotheses 77: 1-2.
30. Waterman M, Ben-Izhak O, Eliakim R, Groisman G, Vlodavsky I, et al. (2007) Heparanase upregulation by colonic epithelium in inflammatory bowel disease. Mod Pathol 20: 8-14.
31. Li RW, Freeman C, Yu D, Hindmarsh EJ, Tymms KE, et al. (2008) Dramatic regulation of heparanase activity and angiogenesis gene expression in synovium from patients with rheumatoid arthritis. Arthritis Rheum 58: 1590-1600.
32. de Mestre AM, Staykova MA, Hornby JR, Willenborg DO, Hulett MD (2007) Expression of the heparan sulfate-degrading enzyme heparanase is induced in infiltrating CD4+ T cells in experimental autoimmune encephalomyelitis and regulated at the level of transcription by early growth response gene 1. J Leukoc Biol 82: 1289-1300.
33. Irony-Tur-Sinai M, Vlodavsky I, Ben-Sasson SA, Pinto F, Sicsic C, et al. (2003) A synthetic heparin-mimicking polyanionic compound inhibits central nervous system inflammation. J Neurol Sci 206: 49-57.
34. Hershkoviz R, Mor F, Miao HQ, Vlodavsky I, Lider O (1995) Differential effects of polysulfated polysaccharide on experimental encephalomyelitis, proliferation of autoimmune T cells, and inhibition of heparanase activity. J Autoimmun 8: 741-750.
35. Bitan M, Weiss L, Reibstein I, Zeira M, Fellig Y, et al. (2010) Heparanase upregulates Th2 cytokines, ameliorating experimental autoimmune encephalitis. Mol Immunol 47: 1890-1898.
36. Campo GM, Avenoso A, Campo S, Traina P, D'Ascola A, et al. (2009) Glycosaminoglycans reduced inflammatory response by modulating toll-like receptor-4 in LPS-stimulated chondrocytes. Arch Biochem Biophys 491: 7-15.
37. Wood RJ, Hulett MD (2008) Cell surface-expressed cation-independent mannose 6-phosphate receptor (CD222) binds enzymatically active heparanase independently of mannose 6-phosphate to promote extracellular matrix degradation. J Biol Chem 283: 4165-4176.
38. Poon IK, Hulett MD, Parish CR (2010) Histidine-rich glycoprotein is a novel plasma pattern recognition molecule that recruits IgG to facilitate necrotic cell clearance via FcgammaRI on phagocytes. Blood 115: 2473-2482.
39. Poon IK, Goodall KJ, Phipps S, Chow JD, Pagler EB, et al. (2014) Mice deficient in heparanase exhibit impaired dendritic cell migration and reduced airway inflammation. Eur J Immunol 44: 1016-1030.
40. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F (1999) Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 274: 10689-10692.
41. Vanlandschoot P, Van Houtte F, Ulrichts P, Tavernier J, Leroux-Roels G (2005) Immunostimulatory potential of hepatitis B nucleocapsid preparations: lipopolysaccharide contamination should not be overlooked. J Gen Virol 86: 323- 331.
42. Tsan MF, Gao B (2004) Cytokine function of heat shock proteins. Am J Physiol Cell Physiol 286: C739-C744.
43. Konno S, Hoshi T, Taira T, Plunkett B, Huang SK (2005) Endotoxin contamination contributes to the in vitro cytokine-inducing activity of osteopontin preparations. J Interferon Cytokine Res 25: 277-282.
44. McKenzie EA (2007) Heparanase: A target for drug discovery in cancer and inflammation. Br J Pharmacol 151: 1-14.
45. Irie F, Okuno M, Matsumoto K, Pasquale EB, Yamaguchi Y (2008) Heparan sulfate regulates ephrin-A3/EphA receptor signaling. Proc Natl Acad Sci U S A 105: 12307-12312.
46. Johnson GB, Brunn GJ, Kodaira Y, Platt JL (2002) Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol 168: 5233-5239.
47. Courtney SM, Hay PA, Buck RT, Colville CS, Phillips DJ, et al. (2005) Furanyl- 1, 3-thiazol-2-yl and benzoxazol-5-yl acetic acid derivatives: novel classes of heparanase inhibitor. Bioorg Med Chem Lett 15: 2295-2299.
48. Naparstek E, Slavin S, Weiss L, Sidi H, Ohana M, et al. (1993) Low-dose heparin inhibits acute graft versus host disease in mice. Bone Marrow Transplant 12: 185-189.
49. Sciumbata T, Caretto P, Pirovano P, Pozzi P, Cremonesi P, et al. (1996) Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long-term survival. Invasion Metastasis 16: 132- 143.
50. Arancibia SA, Beltran CJ, Aguirre IM, Silva P, Peralta AL, et al. (2007) Toll-like receptors are key participants in innate immune responses. Biol Res 40: 97-112.
51. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, et al. (1999) Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 162: 3749-3752.
52. Akbarshahi H, Axelsson JB, Said K, Malmstrom A, Fischer H, et al. (2011) TLR4 dependent heparan sulphate-induced pancreatic inflammatory response is IRF3-mediated. J Transl Med 9: 219.
53. Zhang Z, Chen N, Liu JB, Wu JB, Zhang J, et al. (2014) Protective effect of resveratrol against acute lung injury induced by lipopolysaccharide via inhibiting the myd88dependent Toll-like receptor 4 signaling pathway. Mol Med Rep 10: 101-106.
54. Vince JE, Chau D, Callus B, Wong WW, Hawkins CJ, et al. (2008) TWEAKFN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha. J Cell Biol 182: 171-184.
55. Baker AB, Chatzizisis YS, Beigel R, Jonas M, Stone BV, et al. (2010) Regulation of heparanase expression in coronary artery disease in diabetic, hyperlipidemic swine. Atherosclerosis 213: 436-442.
56. Liu X, Fang H, Chen H, Jiang X, Fang D, et al. (2012) An artificial miRNA against HPSE suppresses melanoma invasion properties, correlating with a down-regulation of chemokines and MAPK phosphorylation. PLoS One 7: e38659.
57. Mitchell MD, Simpson KL, Keelan JA (2004) Paradoxical proinflammatory actions of interleukin-10 in human amnion: potential roles in term and preterm labour. J Clin Endocrinol Metab 89: 4149-4152.
58. Sharif MN, Tassiulas I, Hu Y, Mecklenbrauker I, Tarakhovsky A, et al. (2004) IFN-alpha priming results in a gain of proinflammatory function by IL-10: implications for systemic lupus erythematosus pathogenesis. J Immunol 172: 6476-6481.
59. Webb LM, Ehrengruber MU, Clark-Lewis I, Baggiolini M, Rot A (1993) Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin 8. Proc Natl Acad Sci U S A 90: 7158-7162.
60. Proudfoot AE, Handel TM, Johnson Z, Lau EK, LiWang P, et al. (2003) Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci U S A 100: 1885-1890.
61. Brennan TV, Lin L, Huang X, Cardona DM, Li Z, et al. (2012) Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation. Blood 120: 2899-2908.
62. Burnett MS, Lee CW, Kinnaird TD, Stabile E, Durrani S, et al. (2005) The potential role of resistin in atherogenesis. Atherosclerosis 182: 241-248.
63. Novick D, Barak S, Ilan N, Vlodavsky I (2014) Heparanase interacts with resistin and augments its activity. PLoS One 9: e85944.
64. Freeman C, Parish CR (1998) Human platelet heparanase: purification, characterization and catalytic activity. Biochem J 330 (Pt 3): 1341-1350.
65. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, et al. (1998) Targeted disruption of the MyD88 gene results in loss of IL-1- And IL-18- mediated function. Immunity 9: 143-150.